Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Studentbostäder i Norden AB in connection with its rights issue
Mandate

Vinge has advised Studentbostäder i Norden AB in connection with its rights issue

April 25, 2025 Capital Markets and Public M&A

Vinge has advised Studentbostäder i Norden AB (publ), a real estate company whose shares are listed on Nasdaq First North Premier Growth Market, in connection with an oversubscribed rights issue amounting to approximately SEK 145 million before deduction of transaction costs.

The new shares issued in the rights issue are expected to be admitted to trading on Nasdaq First North Premier Growth Market on or around 7 May 2025.

Studentbostäder i Norden AB (publ) owns, manages and develops student housing in long term partnerships with municipalities, counties and universities. The company’s shares are listed in Sweden on Nasdaq First North Premier Growth Market under the ticker STUDBO.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg, Benjamin Vafaeian, Johannes Akyol and Elias Kröger.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026